The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary fibrosis (IPF). The main end point in the study was lung function based ...
Idiopathic Pulmonary Fibrosis (IPF) is a frightening, incurable disease where the lungs become increasingly damaged by scar tissue, resulting in breathing getting progressively more difficult.